Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Negotiations End, Approval Process Ongoing

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry still working on ratifying draft commitment letter.

You may also be interested in...



Generic User Fee Talks Reach 'Final Wording' But Still Not Done

FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program

Next iteration of PDUFA will feature new communication plans that allow FDA and sponsors to drop mid-review meetings if desired.

FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Office of Generic Drugs reviewed more than 90% of official GDUFA backlog of pending applications, but many still will require more work.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel